Lexeo Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 11, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 11, 2024
LXEO$3.06-2.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Revenue | ||
| Grant revenue | $— | $654 |
| Total revenue | — | 654 |
| Operating expenses | ||
| Research and development | 53,130 | 49,162 |
| General and administrative | 15,383 | 12,001 |
| Total operating expenses | 68,513 | 61,163 |
| Operating loss | (68,513) | (60,509) |
| Other income and expense | ||
| Loss on fair value adjustment to convertible SAFE Note | (530) | — |
| Other income (expense), net | (13) | (2) |
| Interest expense | (205) | (91) |
| Interest income | 2,867 | 1,325 |
| Total other income and expense | 2,119 | 1,232 |
| Loss from operations before income taxes | (66,394) | (59,277) |
| Income taxes | — | — |
| Net loss and comprehensive loss | $(66,394) | $(59,277) |
| Net loss per common share, basic and diluted | $(12.40) | $(36.36) |
| Weighted average number of shares outstanding used in computation of net loss per common share, basic and diluted | 5,354,368 | 1,630,348 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.